Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Quest Diagnostics (DGX) will offer Roche's FDA-cleared pTau217 blood test for Alzheimer's assessment, expanding its AD-Detect® portfolio. The test will be available Q4 2026. Quest also launches a new multi-biomarker AD-Detect test with a 10% indeterminate rate, aiming to provide more actionable insights for patients.
How this was made
The 30-second read
Why it matters
The FDA clearance of Roche's pTau217 assay and Quest's new multi‑biomarker panel represent a significant expansion of non‑invasive diagnostic options, potentially increasing test volumes and revenue.
Market read
First FDA‑cleared single‑assay blood test for Alzheimer’s pathology; could shift testing paradigm and benefit Quest's top‑line.
What to watch
Reimbursement policies and insurance coverage decisions will heavily influence commercial uptake.
Background
Quest Diagnostics is a leading U.S. diagnostic services provider with a broad test menu; the AD‑Detect suite targets early detection of Alzheimer’s disease.
Ticker impact
Quest Diagnostics announced the launch of an FDA‑cleared Roche pTau217 blood test and a new multi‑biomarker AD‑Detect panel, expanding its Alzheimer’s diagnostics portfolio.
Potential modest upside as investors price in incremental revenue from the new test.
Large‑cap diagnostic firm adding a first‑in‑class FDA‑cleared assay; early adoption expected in specialty and primary care.
Market effects
Strengthens the biotech diagnostics sector and may spur competitor launches of similar blood‑based Alzheimer’s tests.
U.S. healthcare providers gain broader access to non‑invasive Alzheimer’s screening.
Sets a precedent for FDA‑cleared neuro‑degenerative biomarkers worldwide.
Counterpoint
Adoption could be slower than expected if clinicians remain skeptical of blood‑based diagnostics versus PET/CSF methods.
Key entities
- companyQuest Diagnostics
NYSE‑listed diagnostics provider (ticker DGX).
- companyRoche
Developer of the FDA‑cleared Elecsys pTau217 assay.
